The level of β2M served as a prognostic biomarker, which was strongly associated with poor overall survival in patients with diffuse large B-cell lymphoma [31], mantle cell lymphoma [32], follicular lymphoma [33], Hodgkin lymphoma [34], and angioimmunoblastic T-cell lymphoma [35]. This evidence concerns the gene B2M and follicular lymphoma.